Israeli AIDS cure developer mulls TASE IPO

The drug to cure AIDS discovered by the Hebrew University of Jerusalem’s Prof. Abraham Loyter is now being developed by Zion Pharmaceutical – a company that currently looks for a CEO, because its private investors want to stay anonymous.

Last week, a new HIV treatment hit the headlines, after it had been tested in the blood of ten patients and found effective in the destruction of cells infected with AIDS – without damaging healthy cells. The drug was developed by Prof. Abraham Loyter from the Hebrew University, and the technology has been commercialized through a company called Zion Pharmaceutical by Yissum, the Hebrew University’s technology commercialization company. “Globes” has learned that the company, led by private investors who meanwhile maintain their anonymity, is considering an offering, probably on the Tel Aviv Stock Exchange. At this stage, the company does not have a CEO.

One of the company’s investors is Arie Ovadia, a board member, consultant and investor in many companies, including several medical technology companies

“The company was founded two and a half years ago and raised about $4 million. The financing was aimed at developing Prof. Loyter’s technology for AIDS and cancer treatment,” Ovadia told “Globes” in an exclusive interview. “We are currently spending about $150,000-200,000 per month and will require a further financing round in 4-7 months. We conducted a meeting at the Tel Aviv Stock Exchange, but we probably need a larger sum than the local stock exchange could offer. We might choose to combine a private fund raising with a public offering, both in the US and in Israel. We plan on starting a road show in the US in a few months.”

Continue reading on Globes